Kiadis Pharma N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
01 jul 2016 - 07:00
Statutaire naam
Kiadis Pharma N.V.
Titel
Kiadis Pharma issues new shares to participants in its Exit Participation Plan
Bericht
Amsterdam, The Netherlands, July 1, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it will issue a total of 338,239 new ordinary shares to the participants in its Exit Participation Plan, which was previously implemented to provide incentives to certain executives and key employees of the Company.
Datum laatste update: 01 september 2024